SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a
clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of cancer, today announced the pricing of its previously announced
underwritten public offering of 6,830,000 shares of its common stock at a price to the public of $10.25 per share. Gross
proceeds to Calithera from the offering are expected to be approximately $70.0 million, before deducting underwriting discounts and
commissions and estimated offering expenses. All of the shares of common stock are being offered by Calithera. In addition,
Calithera has granted the underwriters a 30-day option to purchase up to 1,024,500 of additional shares of common stock at the
public offering price. The offering is expected to close on March 27, 2017, subject to customary closing conditions.
Leerink Partners is acting as sole book-running manager for the offering. Wells Fargo Securities is acting as a
lead manager and JMP Securities is acting as a co-manager for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and
Exchange Commission (SEC), and was declared effective on November 24, 2015. A preliminary prospectus supplement and
accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at
www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related
to the offering may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA, 02110, by email at syndicate@leerink.com, or by telephone at (800) 808-7525, ext. 6132.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing
novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera is
headquartered in South San Francisco, California.
Investor Relations Contact: Jennifer McNealey ir@Calithera.com 650-870-1071
